CN101067149A - Cyp3a检测芯片及其应用 - Google Patents
Cyp3a检测芯片及其应用 Download PDFInfo
- Publication number
- CN101067149A CN101067149A CN 200610119553 CN200610119553A CN101067149A CN 101067149 A CN101067149 A CN 101067149A CN 200610119553 CN200610119553 CN 200610119553 CN 200610119553 A CN200610119553 A CN 200610119553A CN 101067149 A CN101067149 A CN 101067149A
- Authority
- CN
- China
- Prior art keywords
- seq
- dna
- sequence
- artificial sequence
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 title claims abstract description 101
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 title claims abstract description 83
- 239000000523 sample Substances 0.000 claims abstract description 96
- 239000002773 nucleotide Substances 0.000 claims abstract description 43
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000000295 complement effect Effects 0.000 claims abstract description 16
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims abstract 2
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 claims abstract 2
- 238000009396 hybridization Methods 0.000 claims description 45
- 238000001514 detection method Methods 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 239000007790 solid phase Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 9
- 101150116544 CYP3A4 gene Proteins 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 7
- 101150052538 CYP3A5 gene Proteins 0.000 claims description 6
- 101150061952 CYP3A7 gene Proteins 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims description 6
- 238000005215 recombination Methods 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 31
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 abstract description 25
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 abstract description 25
- 108090000623 proteins and genes Proteins 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000007614 genetic variation Effects 0.000 abstract 1
- 238000011337 individualized treatment Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 161
- 230000000694 effects Effects 0.000 description 18
- 230000003321 amplification Effects 0.000 description 16
- 238000003199 nucleic acid amplification method Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 101150051438 CYP gene Proteins 0.000 description 9
- 238000013467 fragmentation Methods 0.000 description 9
- 238000006062 fragmentation reaction Methods 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- -1 DNA-RNA mosaic Proteins 0.000 description 8
- 238000013016 damping Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000002974 pharmacogenomic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000036267 drug metabolism Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 102100038696 Cytochrome P450 3A43 Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 101000957698 Homo sapiens Cytochrome P450 3A43 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- YBJHBAHKTGYVGT-ZXFLCMHBSA-N 5-[(3ar,4r,6as)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@H]2[C@@H](CCCCC(=O)O)SC[C@H]21 YBJHBAHKTGYVGT-ZXFLCMHBSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 101150010856 CRT gene Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229920004463 Voltalef® Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001343 alkyl silanes Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 231100000586 procarcinogen Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000005369 trialkoxysilyl group Chemical group 0.000 description 1
- ZDHXKXAHOVTTAH-UHFFFAOYSA-N trichlorosilane Chemical compound Cl[SiH](Cl)Cl ZDHXKXAHOVTTAH-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
3A4-15603C | 3A4-15603G | 3A4-15603T | 3A4-13908G | 3A4-13908A | 3A4-13908T | 3A4-l5615T | 3A4-15615C | 3A4-15615A |
3A4-20070T | 3A4-20070C | 3A4-20070A | 3A4-20230G | 3A4-20230A | 3A4-20230T | 3A4-21867C | 3A4-21867T | 3A4-21867A |
3A4-21896C | 3A4-21896T | 3A4-21896A | 3A4-22026C | 3A4-22026T | 3A4-22026A | 3A4-25890N | 3A4-25890A | 3A4-25890T |
3A4/-392A | 3A4/-392G | 3A4/-392T | 3A5-3775A | 3A5-3775G | 3A5-3775T | 3A5-27289C | 3A5-27289A | 3A5-27289T |
3A5-3699C | 3A5-3699T | 3A5-3699A | 3A5-6986G | 3A5-6986A | 3A5-6986T | 3A5-12952T | 3A5-12952C | 3A5-12952A |
3A5-14665A | 3A5-14665G | 3A5-14665T | 3A5-14690G | 3A5-14690A | 3A5-14690T | 3A5-19386G | 3A5-19386A | 3A5-19386T |
3A5-27132N | 3A5-27132T | 3A5-27132A | 3A5-31611T | 3A5-31611C | 3A5-31611A | 3A5-29753T | 3A5-29753c | 3A5-29753g |
3A7/-314C | 3A7/-314T | 3A7/-314G | 3A7-26041C | 3A7-26041G | 3A7-26041A | 3A7/-232A | 3A7/-232C | 3A7/-232G |
3A7/-91G | 3A7/-91A | 3A7/-91C | 3A7/-49G | 3A7/-49A | 3A7/-49T | 3A7/-262T | 3A7/-262A | 3A7/-262G |
3A7-4011N | 3A7-4011T | 3A7-4011G | 3A7/-291G | 3A7/-291G*1C | 3A7/-291T | 3A7/-291T*1C | 3A7/-291A | 3A7/-284T |
3A7/-284T*1C | 3A7/-284A | 3A7/-284A*1C | 3A7/-284C | 3A7/-282T | 3A7/-282T*1C | 3A7/-282C | 3A7/-282C*1C | 3A7/-282A |
3A7/-281A | 3A7/-281A*1C | 3A7/-281T | 3A7/-281T*1C | 3A7/-281G | 3A7/-270T | 3A7/-270T*1C | 3A7/-270G | 3A7/-270G*1C |
3A7/-270T | 杂交阴性探针 | 杂交阴性探针 | 杂交阳性探针 | 杂交阳性探针 | CY3 | CY3 | 定位探针 | 定位探针 |
Claims (15)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101195534A CN101067149B (zh) | 2006-12-13 | 2006-12-13 | Cyp3a检测芯片及其应用 |
PCT/CN2007/001853 WO2008011787A1 (fr) | 2006-07-17 | 2007-06-12 | Puce permettant de détecter la mutation génétique du gène cytochrome p450 et utilisation de celle-ci |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101195534A CN101067149B (zh) | 2006-12-13 | 2006-12-13 | Cyp3a检测芯片及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101067149A true CN101067149A (zh) | 2007-11-07 |
CN101067149B CN101067149B (zh) | 2010-12-29 |
Family
ID=38879843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101195534A Active CN101067149B (zh) | 2006-07-17 | 2006-12-13 | Cyp3a检测芯片及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101067149B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101812524A (zh) * | 2010-04-09 | 2010-08-25 | 广州益善生物技术有限公司 | Cyp3a5基因snp检测特异性引物、液相芯片和检测方法 |
CN102676652A (zh) * | 2011-03-09 | 2012-09-19 | 爱科来株式会社 | Cyp3a基因的多态性检测用探针、多态性检测方法、药效评价方法以及多态性检测用试剂盒 |
CN104212904A (zh) * | 2014-09-17 | 2014-12-17 | 武汉康录生物技术有限公司 | 一种用于快速检测人类cyp2c19基因多态性的试剂盒及其使用方法 |
CN104293920A (zh) * | 2014-09-17 | 2015-01-21 | 武汉康录生物技术有限公司 | 一种用于快速检测人类vkorc1和cyp2c9基因多态性的试剂盒及其使用方法 |
CN105274221A (zh) * | 2015-10-14 | 2016-01-27 | 北京晋祺生物科技有限公司 | 一种cyp3a5*3的检测试剂盒 |
JP2016192940A (ja) * | 2015-04-01 | 2016-11-17 | 東洋鋼鈑株式会社 | CYP3A4*1b検出用プローブ及びCYP3A5*3検出用プローブ |
CN110093415A (zh) * | 2019-04-30 | 2019-08-06 | 上海百傲科技股份有限公司 | 检测cyp3a5基因的方法、试剂盒、引物对及探针 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1544652A (zh) * | 2003-10-27 | 2004-11-10 | 上海第二医科大学附属第九人民医院 | 头颈鳞癌分子分类诊断用小型化寡核苷酸芯片 |
-
2006
- 2006-12-13 CN CN2006101195534A patent/CN101067149B/zh active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101812524A (zh) * | 2010-04-09 | 2010-08-25 | 广州益善生物技术有限公司 | Cyp3a5基因snp检测特异性引物、液相芯片和检测方法 |
CN101812524B (zh) * | 2010-04-09 | 2012-08-22 | 广州益善生物技术有限公司 | 一种cyp3a5基因snp检测特异性引物和液相芯片 |
CN102676652A (zh) * | 2011-03-09 | 2012-09-19 | 爱科来株式会社 | Cyp3a基因的多态性检测用探针、多态性检测方法、药效评价方法以及多态性检测用试剂盒 |
CN104212904A (zh) * | 2014-09-17 | 2014-12-17 | 武汉康录生物技术有限公司 | 一种用于快速检测人类cyp2c19基因多态性的试剂盒及其使用方法 |
CN104293920A (zh) * | 2014-09-17 | 2015-01-21 | 武汉康录生物技术有限公司 | 一种用于快速检测人类vkorc1和cyp2c9基因多态性的试剂盒及其使用方法 |
CN104212904B (zh) * | 2014-09-17 | 2016-05-04 | 武汉康录生物技术有限公司 | 一种用于快速检测人类cyp2c19基因多态性的试剂盒及其使用方法 |
CN104293920B (zh) * | 2014-09-17 | 2016-05-04 | 武汉康录生物技术有限公司 | 一种用于快速检测人类vkorc1和cyp2c9基因多态性的试剂盒及其使用方法 |
JP2016192940A (ja) * | 2015-04-01 | 2016-11-17 | 東洋鋼鈑株式会社 | CYP3A4*1b検出用プローブ及びCYP3A5*3検出用プローブ |
CN105274221A (zh) * | 2015-10-14 | 2016-01-27 | 北京晋祺生物科技有限公司 | 一种cyp3a5*3的检测试剂盒 |
CN110093415A (zh) * | 2019-04-30 | 2019-08-06 | 上海百傲科技股份有限公司 | 检测cyp3a5基因的方法、试剂盒、引物对及探针 |
Also Published As
Publication number | Publication date |
---|---|
CN101067149B (zh) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100343389C (zh) | 基因突变检出法 | |
CN100339482C (zh) | 奈瑟球菌蛋白质的杂交表达 | |
CN1286985C (zh) | 与疾病相关的核酸 | |
CN1539994A (zh) | 传染性病原体检测用探针和探针组以及载体和基因检查方法 | |
CN101067149A (zh) | Cyp3a检测芯片及其应用 | |
CN1497049A (zh) | 雄激素受体复合物-相关蛋白 | |
CN1500144A (zh) | 扩增的核酸及其固定化制品 | |
CN1912139A (zh) | 细胞色素p450基因遗传变异的检测芯片及其应用 | |
CN1877328A (zh) | 用23s核糖体基因探针阵列检测水生动物病原菌的方法 | |
CN101045945A (zh) | 检测多种常见细菌病原体的基因芯片、制备方法、试剂盒 | |
CN1687454A (zh) | 基于环介导的等温扩增技术的血液病毒核酸筛查方法 | |
CN1616676A (zh) | 稳定的杂交体 | |
CN1928118A (zh) | 无需核酸标记的基因芯片及其应用 | |
CN101067152A (zh) | 心脑血管疾病的药物遗传学检测芯片及其应用 | |
CN1276094C (zh) | 用于诊断地中海贫血的dna芯片 | |
CN1308462C (zh) | 个体化用药基因型诊断芯片及其制造方法和应用方法 | |
CN1678741A (zh) | 用于检测基因多态性的方法 | |
CN1173989C (zh) | 石斛的dna序列及利用该序列鉴定其品种或辨别其真伪的方法 | |
CN1526111A (zh) | 可用于评估干扰素疗效的多态标记 | |
CN1877327A (zh) | 利用核糖体操纵子间区探针检测水生动物病原菌的方法 | |
CN101037690A (zh) | 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体 | |
CN1169969C (zh) | Ret寡核苷酸微芯片及其用于检测遗传性癌症的方法 | |
CN1961074A (zh) | 包含与ⅱ型糖尿病有关的单核苷酸多态性的多核苷酸、包含该多核苷酸的微阵列和诊断试剂盒以及使用它们分析多核苷酸的方法 | |
CN1639568A (zh) | 用于固定配体的载体 | |
CN1782096A (zh) | 利用zip编码的pna芯片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shanghai Biotechnology Corporation Assignor: Shanghai Biochip Co., Ltd Contract record no.: 2011310000186 Denomination of invention: CYP3A detecting chip and its application Granted publication date: 20101229 License type: Exclusive License Open date: 20071107 Record date: 20110905 |
|
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI BIOTECHNOLOGY CORPORATION Free format text: FORMER OWNER: SHANGHAI BIOCHIP CO., LTD Effective date: 20130819 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130819 Address after: 201203 Shanghai city Pudong New Area Zhangjiang libing Road No. 151 Patentee after: Shanghai Biotechnology Corporation Address before: 201203 Shanghai city Pudong New Area Zhangjiang libing Road No. 151 Patentee before: Shanghai Biochip Co., Ltd |